糖肾康胶囊对早期糖尿病肾病患者血清内皮素影响的临床观察

[目的]观察糖肾康胶囊对早期糖尿病肾病(DN)患者血清内皮素的影响,从而探讨其作用机制。[方法]选取糖尿病肾病微量白蛋白尿期患者60例,随机分为治疗组和对照组各30例,两组均应用基础治疗,治疗组同时采用糖肾康胶囊,3粒/次,3次/日,2个月为1个疗程,3个疗程后观察治疗前后血清内皮素-1(EF-1)及尿微量白蛋白排泄率(UAER)、糖化血红蛋白(Hbalc)、胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)的变化,并进行统计学分析。[结果]治疗组治疗后血清ET-1及尿微量白蛋白、TC、TG、LDL、HDL的变化与对照组相比差异有统计学意义。[结论]糖肾康胶囊能够降低血清ET-1的含量,减少尿微量白蛋白,可能是通过改善高凝状态、减少缺血、缺氧状态的作用,而保护内皮细胞、减轻肾小球的硬化。

Clinical observation on effect of Tangshenkang capsule on serumendothelin in patients with diabetic nephropathy in early stage

[Objective] To observe the effect of Tangshenkang capsule on serum Endothelin in patients with diabetic nephropathy (DN) and explore its mechanism. [Methods] The 60 patients with diabetic nephropathy in period of micro-proteinuria were selected. They were randomly divided into treatment group and control group with 30 cases in each group. Basic therapy was applied in both groups. In the treatment group the patients were also received Tangshenkang capsules simultaneously, 3 tablets, three times a day. A therapy course was two months. Three courses later, the excreting ratio of serum ET-1 and micro-albuminuria (UAER), the changes of glycated hemoglobin (Hbalc), cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) were observed before and after treatment. The statistical analysis was performed. [Results] Compared with control group the changes of serum ET-1 and urinary albumin, cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) had significant changes in the treatment group after treatment. [Conclusion] Tangshenkang capsule can reduce the concentration of serum ET-1, decrease microalbuminuria pos-sibly through improving hypercoagulability, reducing ischemia and anoxia and thus protecting the endothelial cells and alleviating the glomerular sclerosis